BMS drug Zenbexus cuts myeloma progression risk by 51% in trial

October 8, 2026 6:59 AM

Bristol Myers Squibb (NYSE: BMY) announced positive topline results from its Phase 3 EXCALIBER-RRMM study, showing that Zenbexus ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found